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Epidermal cytosol of adult humans can bind dexa-
methasone, and this binding resembles that by glucocor-
ticoid receptors of other tissues as judged by 4 criteria: 
affinity of binding, specificity of binding, molecular size 
of receptor-steroid complexes, and ability of these com-
plexes to bind to nuclei. For demonstration of these 
receptors, epidermis can be separated by trypsinization 
but only after preliminary incubation of the skin with 
molybdate ion, which prevents inactivation of receptors 
when h eated to 22 °C. The presence of these receptors 
suggest that glucocorticoids may act directly on the 
epidermis. Five glucocorticoids that are used topically 
all displaced 3H-dexamethasone from the r eceptor in 
vitro but the affinity of this binding correlates imper-
fectly with the potency of the steroids when used in vivo. 
During the past 3 decades, topical glucocorticoids have been 
the agents most used to treat skin diseases. Although there has 
been much study of their percutaneous penetration and some 
study oftheir biological effects, li ttle attention has been directed 
to the subcellular mechanisms by which they act in skin. In 
many other t issues steroid hormones act through their binding 
by intracellular protein receptors. The receptor-steroid com -
plexes th \)n bind to nuclei and stimulate the production of 
mRNA and hence the synth esis of th e specific proteins t hat 
mediate the steroid-induced effects. We detected such receptors 
in epidermis and dermis of newborn mice [1] , many others 
reported them in fibroblasts grown from dermis, and one group 
recently found glucocorticoid receptors in cultured human ker-
atinocytes [2]. We report here that receptors similar to those of 
other t issues also can be demonstrated in epidermis taken 
directly from normal human adu lts. 
MATERIALS AND METHODS 
Tissue Preparation. 
Skin was obtained from plastic surgical procedures such as ma m-
moplasties and abdominoplasties or fro m a mputated breasts or legs. No 
effo_rt was made to assess the hormonal status of the patients, but none 
was known to have been receiving therapy with topical or systemic 
glucot:orticoids. T he skin was kept as close to 4°C as possible except as 
stated below. After subcutaneous fat was scraped away, the epidermis 
and papillary dermis were cut from the reticular dermis with an electric 
dermatone set at 0.3 mm depth. They were incubated at 4 oc in Eagle's 
Minimal Essential Medium (MEM) containing 0.025 M HEPES buffer 
(GIBCO), 0.01 M dith iothreito l (Cal Biochem) , 0.01 M sodium molybdate 
(Sigma), and 0.25% t rypsin (Worthington). After 2 hr, the temperature 
was raised to 22 °C for· 20-30 min. The epidermis was teased off the 
dermis and incubated for 1 hr at 4°C in MEM containing 0.025 M 
HEPES buffer, O.Ql M sodium molybate, 5% fetal calf serum (GIBCO), 
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MEM: minimal essential medium 
PMSF: phenylmethylsulfonyl nuoride 
0.0005 M phenylmethylsulfonyl fluoride (PMSF) (Sigma), and 1 mg/ ml 
soybean trypsin inhibitor (Sigma type liS). Dw·ing the 3.5 hr of 
incubation, the media was gassed intermittently with a mixture con-
taining 40% oxygen-5% cru·bon dioxide- 55% ni trogen. The epidermis 
was rinsed with saline and homogenized with a Polytron PT 10, usually 
at a 1 g/3 ml ratio , in buffer containing 0.25 M sucrose (Mallinck.rodt), 
0.01 M 3-mercapto-1, 2-propanediol (Aldrich) , 0.0015 M EDTA (Sigma) , 
0.01 M sodium molybdate, and 0.05 M Tris H Cl (Baker) at pH 7.4. 
Cytosol was prepared by centrifugation at 218,000 xg for 30 min. 
Protein and DNA concentrations were determined as described [1]. 
Characterization. of Binding 
Determination of the affinity a nd specificity of binding of "H-dexa-
methasone• by cytosol, of binding of "H-dexamethasone-receptor com-
plexes to nuclei, and of the molecular size of the complexes were studied 
as described previously [1]. Briefly, after incubation of cytosol with 60 
nM "H-dexamethasone for 18 hr, unbound ligand was removed by 
adsorption onto dex t ran-charcoal, the latter was removed by centrifu-
gation, and the bound "H remaining in the supernatant was measured 
by use of a scintillation counter. Correction was made for nonspecific 
binding through the use of parallel specimens containing 120 p.M unla-
beled dexamethasone. T o detect binding of complexes to nuclei, the 
cytosol charged with "H-dexamethasone was passed through a 2 X 7 
em column of Bio-Gel P 2. This removed molybdate and other low 
moleculru· weight materials that can inhibi t the activation of the com-
plexes to a form capa ble of binding to nuclei. After incubation for 18 hr, 
the complexes were mixed with nuclei prepru·ed from the livers of 
'<drenalectomized rats and incubated for 1.5 hr. T he nuclei then were 
washed, a nd bound "H was measw·ed. 
RESULTS 
Successful demonstration of receptors requires that epider-
mis be sepaTated from dermis rapidly without heating and 
without expos w-e of the receptors to proteolytic enzymes, either 
of which readily destroys receptor activity. Because molybdate 
ion is known to protect glucocorticoid receptors against heat 
inactivation [3], t he upper skin flrst was incubated with moly-
bate for 2 hr at 4°C. We found that, without molybdate, the 
brief heating to 22°C to allow trypsin to cleave the epidermal-
dermal attachments destroys the receptor activity. Also, incu-
bation of skin in media containing trypsin for 18 hr at 4°C 
destroys specific binding. Similarly, intact epidermis must be 
incubated with antiproteases before homogeniza tion because i.f 
they are added only to the homogenization buffer, the trypsin 
destroys receptor activity before the anti pro teases are effective, 
and trypsinization of frozen and thawed skin destroys all recep-
tor activity. 
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When cytosol was prepared from epidermis obtained by this 
method, binding of 3H-dexamathesone was present in all spec-
• The following trivial names are used: dexamethasone, 9-fluoro-16n-
methyl-11/l,17a,21-trihyd.roxypregna-1,4-diene-3,20-dione: 17 fl-estra-
diol, 1,3,5 (10) -estratriene-3, 17/1-diol ; testosterone, 17/1-hyd.roxy-4 -an-
drosten-3-one; 17a -hydroxyprogesterone, 17-hydroxy-pregn-4-ene-3,20-
dione; progesterone, 4-pregnene-3,20-dione; hydrocort isone, 11/l,17,21-
trihydroxy-4-pregnene-3,20-dione; triamcinolone acetonide, 9-nuoro-
11/J,16a,17 a,21-tetrahydroxy-pregna-1,4-diene-3,20-dione 16,17 -aceto-
nide; dinorasone diacetate, 6a,9a-difluoro-11/J,l7,21-trihydroxy-16/J- I 
methyl-pregna-1,4-diene-3,20-dione 17,21 diacetate; tluocinonide, 6a,9-
difluoro-11/l,16a,17 ,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 
16,17-acetal wi th acetone 21-acetate; betamethasone valerate, 9-fluoro-
11/J,17,21 -trihydroxy-16/1-methylpregna-1 ,4-diene-3,20-dione 17-valeT-
ate; hydrocort isone valerate, 11/J,21-dihydroxy- 17a-valeryloxy-4-preg-
nene-3,20-dione. 
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imens studied. The binding was of high affinity, the apparent 
Kd being 1.1 nM (average of three separate experiments) (Fig 
1), and the concentration of specific binding sites was 0.05 
pmol/mg soluble protein (average of 10 determinations) or 0.6 
pmol/mg DNA (average of 5 determinations) . Using a cytosol 
prepared from an homogenate of 1 g (wet weight) per 1.4 ml 
buffer, typical dpm/sample were as follows: total binding-
11,544, nonspecific binding-4038, blank (buffer used in place 
of cytosol)-1521. 
Cytosol was incubated with 3H -dexamethasone and various 
unlabeled steroids to determine the steroid specificity of the 
3H-dexamethasone binding (Table I). Steroids such as estradiol 
and testosterone that are known not be active glucocorticoids 
competed weakly, whereas cortisol, dexamethasone, and tri-
amcinolone acetonide bound with increasing affinity, paralleling 
their biologic potency. This binding specificity was similar to 
that determined previously for epidermis from newborn mice 
TABLE I. Effect of various steroids on the binding oeH-
dexamethasone by cytosol from epidermis 
Competing steroid 
17 .8-Estradiol 
Testosterone 
17 a -Hydroxyprogesterone 
Progesterone 
Hydrocortisone 
Dexamethasone 
Triamcinolone acetonide 
% Inhibition of "H-dexamethasone 
binding" 
Ratio' 
100 
100 
100 
1 
2 
10 
100 
10 
100 
1 
2 
10 
100 
1 
2 
Human 
8 
16 
63 
3 
7 
45 
91 
64 
95 
51 
68 
89 
96 
69 
86 
Mouse(' 
20 
56 
70 
18 
27 
63 
95 
78 
91 
56 
77 
90 
99 
72 
91 
" (100) (A - S) / (A - D), where A is "H-dexamethasone bound 
without competing steroid, S is 3H-dexamethasone bound in the pres-
ence of a competing steroid, and D is 3H-dexamethasone bound in the 
presence of a 2000-fold excess of unlabeled dexamethasone. The total 
3H-dexamethasone concentration was 60 nM. Each number is the av-
erage of at least 3 independent experiments. 
b Concentration of competing steroid to concentration of 3H-dexa-
methasone. 
' Data from [1]. 
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FIG 1. Binding of aH-dexamethasone to human epidermal cytosol. 
Aliquots of cytosol were incubated with increasing amounts for "H· 
dexamethasone for 18 hr in the presence or absence of a 2000-fold 
excess of unlabeled dexamethasone, and bound radioactivity was mea-
sured after treatment with charcoal-dextran. The curve represents 
specific binding. The inset represents a Scatchru·d analysis of the data 
presented in the main figure. 
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TABLE II. Comparison of clinical potency and receptor binding 
affinity of several g lu.cocorticoids commonly used topically 
Commercial 
Potency" concentration Human Mouse 
(%) epidermis skin (nM} (nM) 
Diflorasone diacetate I 0.05 20 33 
Fluocinonide I 0.05 11 10 
Betamethasone valerate IV 0.1 5 6 
Triamcinolone acetonide IV 0.1 17 14 
Hydrocortisone valerate IV 0.2 9 18 
"References 4-7. 
"Cytosol was incubated with 60 nM 3H-dexamethasone and 3 differ-
ent concentrations of the competing steroid. The percentage inhibition 
of binding was plotted versus the log concentration of competing 
steroid. !Coo = the concentration at which 50% inhibit ion occurred. 
Values are the averages of 3 sepru·ate determinations. 
BD G y 
I I I 
100 
A 0 H 
I I I 
150 
ELUTION VOLUME, ml 
v 
I 
FIG 2. Agru·ose A 1.5 m chromatogram of human epidermal cytosol 
charged with 3H-dexamethasone. Cytosol was incubated for 20 h~· with 
"H-dexamethasone (60 nM) , treated with chru·coal-dextran, applied to 
a 1.2 X 155 em glass column of Bio-Gel A 1.5 m (200-400 :nesh, from 
BioRad) in homogenization buffer with 0.4 M KCl, and elu ted with the 
same buffer at 4°C. BD =blue dextran, G = ,8-galactosidase, Y =yeast 
alcohol dehydrogenase, A = bovine serum albumin, 0 = chicken egg 
albumin, H = hemoglobin, V = 14C-valine. 
7 
'· 
6 G\PIDERMOS 
5 
4 
y\ 
Rs , nm Ae\ 
3 
o• \ 
He\ 
2 
0 .2 0.4 0.6 0.8 
Kov 
FIG 3. Calibration plot for evaluation of the Stokes' radius (Rs) of 
"H-dexa methasone-receptor complexes according to their distribution 
coefficient [I]. The proteins used as standards are those of Fig. 2. 
(Table I). In addition, more careful competition studies were 
performed with five glucocorticoids available commercially for 
topical use (Table II) . Clinical activity, as measUTed by vaso-
constrictor assay, and therapeutic potency [ 4-7], and receptor 
binding affinity using cytosol of human epidermis or mouse 
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skin, as measured by IC50, were not correlated within this group. 
Receptor-3H-dexamethasone complexes were eluted from 
agarose at a position corresponding to a Stokes' radius of 6.1 
nm (Fig 2 and 3). As with glucocorticoid-receptor complexes of 
mouse skin, the elution peak routinely was twice as broad as 
that of the proteins used to calibrate the column. The smaller 
peak of bound 3H-dexamethasone eluting at 160 ml was not 
present in previous studies of mouse skin cytosol and may 
indicate minor amounts of proteolysis by the trypsin used to 
separate epidermis and dermis. 
Nuclear uptake of 3H-dexamethasone from charged cytosols 
was proportional to the amount of steroid specifically bound to 
receptors. After 15 hl' of incubation at 0°C, 24% of added 
specifically bound 3H-dexamethasone was bound to the nuclei 
(average of 3 experiments). This is somewhat less than that 
bound using cytosol of mouse epidermis separated by dithio-
threitol (approximately 35%) [1], but when cytosol was prepared 
from mouse epidermis that had been separated by trypsin as 
was the human epidermis, only 26% of added specifically bound 
3H-dexamathasone was taken up by the nuclei. When specific 
cytosolic binding was destroyed by heating to 37°C or by 
addition of excess unlabeled dexamethasone, no 3H was bound 
to the nuclei. Also, when cytosol was not passed over P 2 or 
when molybdate was added to the cytosol after chTomotogra-
phy to prevent activatjon, less than 4% of the specifically bound 
3H-dexamethasone became bound to the nuclei. 
DISCUSSION 
When epidermis was separated carefully from dermis, cyto-
solic binding of 3H-dexamethasone was detected readily. This 
binding appears to be similar to that of receptors in other 
tissues by 4 criteria: (i) affinity of binding, (ii) specificity of 
binding, (iii) molecular size of receptor-steroid complexes, and (iv) ability of cytosol receptor-steroid complexes to bind to 
nuclei. Tht; quantity of binding, 0.05 pmoljmg protein, is similar 
to that in epidermis of newborn mice, 0.04 pmol/mg protein, 
but somewhat less than that in cultured keratinocytes, 0.20 
pmoljmg protein [2]. The reduced amount could be due to 
methodologic variations, real differences in receptor content 
between cells in vitro and in vivo, or possibly our incomplete 
detection of receptors that had bound glucocorticoids endoge-
nously and were attached to nuclei and therefore not in the 
cytosol . 
Because glucocorticoids vary in their t herapeutic potency, we 
studied more carefully 5 such compounds so that comparison 
could be made between biologic activity and receptor binding. 
Although all 5 were bound strongly, the affinity did not pru·allel 
their clinical potency as measured by vasoconstriction and 
therapeutic potency. Thus betamethasone valerate was bound 
approximately twice as firmly as fluocinonide and approxi-
mately 4 times as fumly as diflorasone diacetate, and yet the 
latter two appear to be more potent clinically even at concen-
trations only half that of betamethasone valerate [5,8]. Simi-
larly, hydl'ocortisone valerate is bound more strongly than the 
other steroids tested except betamethasone valerate and yet 
clinically is no more potent even when used at two to four times 
the concentration of tbe other steroids. Ponec, Kempenaar, and 
De Kloet [2] also found that betamethasone valerate was bound 
with an affinity greater than expected by its clinical potency 
but, in contrast to our studies, noted that binding affinities of 
Vol. 78, No.2 
several other steroids did pru·allel their in vivo activity. A lack 
of strict correlation between binding affinity and potency mea-
sured by bioassay has been found in other systems [9] and may 
be due to differences in steroid availability and metabolic 
transformation in the tissue and perhaps to differences in 
nuclear binding of receptor-ligand complexes. When considering 
topical glucocorticoid preparations, the imperfect correlation 
also may be attributable to differences in release of steroid from 
the vehicle and penetration across the stratum corneum, be-
cause potency of a single glucocorticoid may be quite variable 
when it is in different bases [10]. Furthermore, in these studies 
we measured binding to receptors of epidermis, whereas vaso-
constriction assays and even therapeutic efficacy might depend 
more on effects on dermal cells. However, the similarity of 
affinity of binding with which these five glucocorticoids ru·e 
bound by adult human epidermis and newborn mouse skin 
suggests a careful conservation of these receptor molecules 
during evolution. 
The presence of glucocorticoid receptors suggests that human 
epidermis may be affected directly by these agents. However, 
their presence is not proof that they mediate the pharmacologic 
effects of glucocorticoids. Indeed, one study has suggested that 
clinically useful topical glucocorticoids attain an epidermal 
concentration far greater than that needed to saturate these 
receptors [11]. Further information about theil' pharmacologic 
role might be learned from studies of receptor content in lesions 
resistant to glucocortocoids, but such measw·ement would re-
quire assays more sensitive than those used in this study. 
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especially Drs. Ronald Gruber and Diane Salyer, for their help in 
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